Core Viewpoint - Pro Pharmaceutical (000739) reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in its business operations [1] Financial Performance - The company achieved operating revenue of 5.444 billion yuan, a year-on-year decrease of 15.31% [1] - The net profit attributable to shareholders was 563 million yuan, down 9.89% year-on-year [1] - Basic earnings per share were 0.4861 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 3.4835 yuan (including tax) for every 10 shares to all shareholders [1] Business Segment Performance - The raw material pharmaceutical intermediate business generated sales revenue of 3.603 billion yuan, a year-on-year decline of 23.41% [1] - Gross profit from this segment was 493.48 million yuan, down 35.32% year-on-year [1] - The gross margin for this segment was 13.70%, a decrease of 2.52 percentage points year-on-year [1]
普洛药业:上半年净利润同比下降9.89% 拟每10股派3.4835元